08:41 AM EDT, 09/04/2024 (MT Newswires) -- Biogen (BIIB) said Wednesday that a study of a higher dose regimen of its drug nusinersen for the treatment of infants with spinal muscular atrophy met its primary six-month endpoint.

The 75-patient higher dose cohort of a phase 2/3 study showed a "statistically significant improvement" in the motor function of infants who received the higher dose of the drug, also known under the brand name Spinraza, compared to a control group, the company said.

Biogen licensed Spinraza from Ionis Pharmaceuticals ( IONS ) .